Disclosures for "First-in-Human Dose Selection and Pharmacokinetics, Safety, Tolerability, and Immunogenicity of ARGX-119, an Agonist Antibody for Human Muscle-Specific Kinase"
-
The institution of Mrs. van Bragt has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for argenx. Mrs. van Bragt has stock in argenx.
-
Dr. Kneip has received personal compensation for serving as an employee of argenx.
-
Author has nothing to disclose
-
Dr. Leng has received personal compensation for serving as an employee of argenx. Dr. Leng has stock in argenx.
-
Dr. Mutch has nothing to disclose.
-
Dr. Patel has nothing to disclose.
-
Dr. Vanhoenacker has received personal compensation for serving as an employee of argenx. Dr. Vanhoenacker has stock in argenx.
-
Dr. Vaghi has received personal compensation for serving as an employee of argenx.
-
Rebecca Shilling has received personal compensation for serving as an employee of Alnylam Pharmaceuticals. Rebecca Shilling has received stock or an ownership interest from Alnylam Pharmaceuticals.
-
Mr. Vanhauwaert has stock in argenx.